-
1
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
DOI 10.1182/blood-2006-03-011239
-
Rousselot, P et al. imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58-60 (2007). (Pubitemid 46053043)
-
(2007)
Blood
, vol.109
, Issue.1
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
Legros, L.4
Cayuela, J.M.5
Maarek, O.6
Blanchet, O.7
Marit, G.8
Gluckman, E.9
Reiffers, J.10
Gardembas, M.11
Mahon, F.-X.12
-
2
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (sTiM) trial
-
Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (sTiM) trial. Lancet Oncol. 11, 1029-1035 (2010).
-
(2010)
Lancet Oncol.
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
-
3
-
-
77958012952
-
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DnA PCR
-
Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DnA PCR. Leukemia 24, 1719-1724 (2010).
-
(2010)
Leukemia
, vol.24
, pp. 1719-1724
-
-
Ross, D.M.1
-
4
-
-
0032211172
-
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
-
Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J. M. & Melo, J. V. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 92, 3362-3367 (1998). (Pubitemid 28492345)
-
(1998)
Blood
, vol.92
, Issue.9
, pp. 3362-3367
-
-
Bose, S.1
Deininger, M.2
Gora-Tybor, J.3
Goldman, J.M.4
Melo, J.V.5
-
5
-
-
77951632041
-
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase
-
Goldman, J. M. et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28, 1888-1895 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1888-1895
-
-
Goldman, J.M.1
-
6
-
-
33745608455
-
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
-
DOI 10.1182/blood-2005-07-2815
-
Koptyra, M. et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108, 319-327 (2006). (Pubitemid 43990645)
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 319-327
-
-
Koptyra, M.1
Falinski, R.2
Nowicki, M.O.3
Stoklosa, T.4
Majsterek, I.5
Nieborowska-Skorska, M.6
Blasiak, J.7
Skorski, T.8
-
7
-
-
77950396947
-
Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (iM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): Confirmatory results at 18 months of part 1 of the spirit phase ii randomized trial of the French CML Group (Fi LMC) [abstract]
-
Guilhot, F. et al. significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (iM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the spirit phase ii randomized trial of the French CML Group (Fi LMC) [abstract]. Blood 114, a340 (2009).
-
(2009)
Blood
, vol.114
-
-
Guilhot, F.1
-
8
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl.J. Med. 355, 2408-2417 (2006). (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
9
-
-
77958595179
-
Long-term prognostic significance of early molecular response to matinib in newly diagnosed chronic myeloid leukemia: An analysis from the international Randomized study of interferon and sTi571 (iRis)
-
Hughes, T. P et al. Long-term prognostic significance of early molecular response to matinib in newly diagnosed chronic myeloid leukemia: an analysis from the international Randomized study of interferon and sTi571 (iRis). Blood 116, 3758-3765 (2010).
-
(2010)
Blood
, vol.116
, pp. 3758-3765
-
-
Hughes, T.P.1
-
10
-
-
34548225514
-
Minimum viable population size: A meta-analysis of 30 years of published estimates
-
DOI 10.1016/j.biocon.2007.06.011, PII S0006320707002534
-
Traill, L. W., Bradshaw, C. J. & Brook, B. W. Minimum viable population size: A meta-analysis of 30 years of published estimates. Biological Conservation 139, 159-166 (2007). (Pubitemid 47320616)
-
(2007)
Biological Conservation
, vol.139
, Issue.1-2
, pp. 159-166
-
-
Traill, L.W.1
Bradshaw, C.J.A.2
Brook, B.W.3
|